Annex A. Science And Technology Objectives (STOs) III.J.04. Antiparasitic Drug Program. By FY98, transition to advanced development antiparasitic drugs capable of preventing or treating malaria or leishmaniasis. Candidates include arteether (parenteral treatment of severe drug resistant malaria), FY96; topical paromomycin/gentamicin (cutaneous leishmaniasis treatment), FY96; Floxacrine analog (malaria treatment), FY98; atovoquone-proguanil (malaria prophylaxis), FY97; artemisinin analog (malaria prophylaxis), FY01.
Supports: Army Modernization Plan, Medical Annex OProject, Sustain, and Protect the Force. The Medical Threat Facing a Force Projection Army (1994). Food and Drug Administration regulatory requirements.
| STO Manager: | TSO: | TRADOC POC: |
| COL W. H. Bancroft | MAJ Mark Seymour | Herbert Russakoff |
| MRMC | SARD-TM | CSS Battle Lab |
| 301-619-7567 | 703-695-5615 | 804-734-0599 |